Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
| Autor: | Ronan T. Swords, Diana Azzam, Hassan Al-Ali, Ines Lohse, Claude-Henry Volmar, Justin M. Watts, Aymee Perez, Ana Rodriguez, Fernando Vargas, Roy Elias, Francisco Vega, Arthur Zelent, Shaun P. Brothers, Taher Abbasi, Jonathan Trent, Shaukat Rangwala, Yehuda Deutsch, Eibhlin Conneally, Leylah Drusbosky, Christopher R. Cogle, Claes Wahlestedt |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Drug Cancer Research Treatment response medicine.medical_specialty media_common.quotation_subject Clinical Decision-Making Antineoplastic Agents Pilot Projects Article Young Adult 03 medical and health sciences 0302 clinical medicine Clinical decision making Internal medicine medicine Humans Precision Medicine Cells Cultured Aged media_common Aged 80 and over business.industry Myeloid leukemia Hematology Middle Aged Precision medicine Response to treatment Surgery Leukemia Myeloid Acute 030104 developmental biology 030220 oncology & carcinogenesis Cohort Female Drug Screening Assays Antitumor business Ex vivo |
| Zdroj: | Leukemia Research. 64:34-41 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2017.11.008 |
| Popis: | A precision medicine approach is appealing for use in AML due to ease of access to tumor samples and the significant variability in the patients' response to treatment. Attempts to establish a precision medicine platform for AML, however, have been unsuccessful, at least in part due to the use of small compound panels and having relatively slow turn over rates, which restricts the scope of treatment and delays its onset. For this pilot study, we evaluated a cohort of 12 patients with refractory AML using an ex vivo drug sensitivity testing (DST) platform. Purified AML blasts were screened with a panel of 215 FDA-approved compounds and treatment response was evaluated after 72h of exposure. Drug sensitivity scoring was reported to the treating physician, and patients were then treated with either DST- or non-DST guided therapy. We observed survival benefit of DST-guided therapy as compared to the survival of patients treated according to physician recommendation. Three out of four DST-treated patients displayed treatment response, while all of the non-DST-guided patients progressed during treatment. DST rapidly and effectively provides personalized treatment recommendations for patients with refractory AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect